Literature DB >> 19725998

Chronic lymphocytic leukaemia: clinical-aetiological findings in 66 patients and their families.

Walter Weber1, Patrick F Maurer, Jacqueline Estoppey, Marcel Zwahlen.   

Abstract

BACKGROUND: Little is known about the aetiology of chronic lymphocytic leukaemia (CLL). The family medical history is a "genomic tool" capturing interactions of genetic susceptibility, shared environment and common behaviours.
METHODS: A cohort of 66 consecutives patients with CLL (probands) was studied in a medical oncology practice (W.W.) from 1981 until 2005. A German version of the NCI medical history questionnaire for cancer aetiology was used. Familial clustering analysis was done by comparing the proportion of specific tumours in the first degree relatives of the CLL practice cohort with corresponding proportions of population-based cancer registry data.
RESULTS: 18 (41%) male and 5 (23%) female CLL probands had multiple malignancies, e.g. 2 meningiomas, 7 and 19 years after diagnosis of CLL. 46 (12%) first degree relatives had malignancies with an excess of CLL. Other conspicuous familial associations are CLL with malignancies of the upper GI tract (oesophagus, stomach) and of the nervous system.
CONCLUSION: 1. Chronic lymphocytic leukaemia clusters in some families like any other disease. Predisposition genes should be searched. 2. Cancer prevention and early detection should be continued in CLL patients because of their longevity and high risk for multiple malignancies. 3. The overrepresentation of upper GI malignancies in first degree relatives of CLL patients calls for targeted oesophago-gastroscopy screening studies.

Entities:  

Year:  2007        PMID: 19725998      PMCID: PMC2736981          DOI: 10.1186/1897-4287-5-4-210

Source DB:  PubMed          Journal:  Hered Cancer Clin Pract        ISSN: 1731-2302            Impact factor:   2.857


Introduction

Every human disease clusters in families to some extent. This is also true for cancer. All sites show an excess of cancers of the same site among relatives, with thyroid and colon cancers and lymphocytic leukaemia showing the highest familial risks [1]. There is also familial clustering of malignancies originating from different primary sites [2]. Taking the family history of cancer patients is a low technology approach which can be applied all over the world [3]. It is a tool to identify high risk persons and families and to down-stage disease by targeted prevention and therapeutic approaches [4]. The family medical history represents a "genomic tool" that can capture interactions of genetic susceptibility, shared environment, and common behaviours in relation to disease risk [5]. It is well suited to research into cancer aetiology, of which little is known in chronic lymphocytic leukaemia (CLL), the most common form of leukaemia [6]. To gain aetiological clues a cancer-related family history in a private oncology practice cohort of 66 subsequent CLL patients has been evaluated.

Materials and methods

A cohort of 66 consecutive patients with CLL was studied in a medical oncology practice (W.W.) from 1981 until 2005. The diagnoses of CLL were made by standard clinical, haematological and immunological criteria. The family history was elicited with a German version of the NCI medical history questionnaire for cancer aetiology [7]. The anamnestic data were verified as far as possible by obtaining copies of medical and pathology reports. Every pedigree was carefully examined for aetiological clues. In addition familial clustering analyses was made by comparing the proportion of specific tumours among all diagnosed tumours in the first degree relatives (FDR) of the probands with corresponding proportions of incidence data of the years 1981 and 1982 in the population of Geneva, Switzerland and of the years 1983–1987 in the population of Basel, Switzerland [8,9].

Results

CLL patients (probands)

The 66 probands were 44 male (median age: 67 years; range 39 years to 85 years) and 22 female (median age: 65 years; range 38 years to 88 years). The age distribution of the probands corresponds to the age distribution of patients in the general population (Kolmogoroff-Smirnoff-test). 47 (71%) CLL were typed immunologically: 46 had B-CLL and 1 had T-CLL. 18 male patients (41%) and 5 female patients (23%) had multiple malignancies (Table 1).
Table 1

Multiple primaries in 23 patients with CLL

First primarySecond primaryThird primaryN. pat.
Male

CLLlung3

CLLliver1

CLLskin (spinalioma)1

CLLprostate1

CLLbladder1

CLLmeningioma1

ProstateCLL3

Skin (melanoma, sweat gland)CLL2

Skin (basalioma)CLLoesophagus1

Skin (basalioma)CLLprostate1

LiposarcomaCLL1

KidneyCLL1

BladderCLL1

Female

CLLanus1

CLLkidney1

CLLmeningioma1

CLLessential thrombocythaemiaanus1

OMFCLL1
Multiple primaries in 23 patients with CLL

First degree relatives (FDR)

46 (12%) of the 372 FDR had malignancies. There was a significant excess of CLL, other leukaemias, and of malignancies of uncertain origin, of oesophagus and brain (Table 2).
Table 2

Malignancies in 46 first degree relatives

Cancer siteMaleFemaleTotal
Uncertain336*

CLL235*

Breast044

Stomach224

Oesophagus303*

Colorectum303

Lung303

Brain303*

Leukaemia033*

Skin022

ENT101

Liver101

C. tissue101

Larynx101

Prostate11

Cervix11

Ovary11

Thyroid101

NHL101

Myeloma101

Other000

Total271946

*p < 0.05, 2-sided Fisher's exact test

Malignancies in 46 first degree relatives *p < 0.05, 2-sided Fisher's exact test In 5 families (8%) CLL occurred in relatives. Affected were mother and sister in one family, fathers in two families, mother and sister in one family each.

Discussion

CLL patients

The CLL patients frequently had multiple primary cancers, confirming previous reports [10]. In our study there is male dominance and CLL is associated with malignancies of the skin, prostate, lung, urinary tract, anus, meninges and bone marrow (myeloproliferative diseases). The observed/expected ratio was 1.20 (95% confidence interval: 1.15–1.26) in a population-based US study [11]. Cancer prevention and early detection should be continued in CLL patients because of their longevity and high risk for second malignancies. These should be treated as they would be in patients without CLL [12].

Families of CLL patients

CLL clusters in some families like any other disease [13]. The transmission pattern suggests a dominant model of heredity [14]. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion [15]. Gains and losses in two regions of the X chromosome, Xp11.2–p21 and Xq21-qter, appear more common in familial CLL than in sporadic CLL [16]. Another candidate region is on chromosome 13 [17]. Predisposition genes should be searched. Serum B-lymphocyte stimulator (BlyS) levels are elevated in patients with familial B-CLL [18]. Elevated BLyS levels correlate with the presence of a T at -871 in the BLyS promoter [18]. In our study oesophageal and brain cancers were overrepresented in male first degree relatives. There were also 4 stomach cancers, not reaching statistical significance. In Bulgaria stomach cancer was particularly often diagnosed in families of CLL patients [19]. In addition one of our CLL patients (woman, 40-years-old at diagnosis) had a brother with duodenal gastrointestinal stomach tumour (GIST) at age 36. The frequent occurrence of upper GI malignancies in FDR of CLL patients calls for targeted oesophago-gastroduodenoscopy screening studies.
  15 in total

1.  Chromosomal imbalances in familial chronic lymphocytic leukaemia: a comparative genomic hybridisation analysis.

Authors:  B Summersgill; P Thornton; S Atkinson; E Matutes; J Shipley; D Catovsky; R S Houlston; M R Yuille
Journal:  Leukemia       Date:  2002-07       Impact factor: 11.528

2.  Research priorities for evaluating family history in the prevention of common chronic diseases.

Authors:  Paula W Yoon; Maren T Scheuner; Muin J Khoury
Journal:  Am J Prev Med       Date:  2003-02       Impact factor: 5.043

Review 3.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

4.  Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders.

Authors:  Anne J Novak; Deanna M Grote; Steven C Ziesmer; Michael P Kline; Michelle K Manske; Susan Slager; Thomas E Witzig; Tait Shanafelt; Timothy G Call; Neil E Kay; Diane F Jelinek; James R Cerhan; Jane A Gross; Brandon Harder; Stacey R Dillon; Stephen M Ansell
Journal:  J Clin Oncol       Date:  2006-01-23       Impact factor: 44.544

Review 5.  Familial cancer diagnosis.

Authors:  W Weber; J Estoppey; H Stoll
Journal:  Anticancer Res       Date:  2001 Sep-Oct       Impact factor: 2.480

6.  National database of familial cancer in Sweden.

Authors:  K Hemminki; P Vaittinen
Journal:  Genet Epidemiol       Date:  1998       Impact factor: 2.135

7.  Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion.

Authors:  Andy C Rawstron; Martin R Yuille; Julie Fuller; Matthew Cullen; Ben Kennedy; Stephen J Richards; Andrew S Jack; Estella Matutes; Daniel Catovsky; Peter Hillmen; Richard S Houlston
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

8.  Second cancer following lymphatic and hematopoietic cancers in Connecticut, 1935-82.

Authors:  M H Greene; J Wilson
Journal:  Natl Cancer Inst Monogr       Date:  1985-12

9.  Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands.

Authors:  D E Goldgar; D F Easton; L A Cannon-Albright; M H Skolnick
Journal:  J Natl Cancer Inst       Date:  1994-11-02       Impact factor: 13.506

Review 10.  Second neoplasms in patients with chronic lymphocytic leukemia.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2004-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.